Scomnet in the spotlight after news of FDA approval


This combination of images provided by Edwards Lifesciences shows the Sapien 3 heart valve expanded, left, and crimped for insertion. AP filepic

PETALING JAYA: Shares of medical cable company Supercomnet Technologies Bhd (Scomnet) have been seeing some interest following news that its largest client, California-based Edwards Lifesciences Corp, has received approval for its heart valve systems from the US Food and Drug Administration (FDA) on Aug 16.

Edwards Lifesciences’ share price hit a record high of US$223.95 on Aug 19.

Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Scomnet , EdwardLifesciences , FDA , approved , valve system ,

   

Next In Business News

Sime’s bold rebrand signals modern focus
Bank Negara allows MDBs and DFIs to issue ringgit bonds
Boxed-in markets seek safety
MSC posts RM14mil net profit in third quarter
Strained by lack of positive catalysts
Kossan’s nine-month earnings surge by 588%
Metro Healthcare makes ACE Market debut
Cropmate seeks to raise RM42mil to buy factories
Malaysia, New Zealand committed on having 'scoping exercise' to strengthen FTA
MSC posts RM14mil net profit in third quarter

Others Also Read